Valued at USD 30.45 billion in 2025, the Keytruda market is projected to reach USD 33.26 billion in 2026 and USD 68.75 billion by 2034, growing at a CAGR of 9.5% during the forecast period 2026–2034. Leading companies include Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, AstraZeneca plc, Pfizer Inc., Novartis AG, Sanofi S.A., Johnson & Johnson, GSK plc,...